Alembic Pharmaceuticals Limited — Updates, 02-05-2025: Press Release

Alembic Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. The company received USFDA final approval for Ticagrelor 90 mg and tentative approval for the 60 mg dose, targeting a US$1.3 billion cardiovascular market. This boosts Alembic’s US generics portfolio, now at 222 ANDA approvals, enhancing its presence in a high-value segment with strong growth potential.